• Agenda

• Brochure

• CE Credit

• Course Director & Faculty

• Registration

Target Audience
Physicians, hematologist-oncologists, nurses and all others interested in hematologic malignancy and hematopoietic stem cell transplantation.

Main Symposium Agenda
7:30-09:00 am Registration

9:00-9:15 am Welcome Remarks: Mohammad Hegazi, MD

9:15-9:45 am Updates in Diffuse Large B Cell Lymphoma: John Leonard, MD

9:50-10:20 am Frontline Treatment of ALL in 2024: Nicholas Short, MD

10:25-10:35  Q & A

10:35-10:55 am  Break

10:55-11:45 am Controversies in Multiple Myeloma: Krina Patel, MD & Saad Usmani, MD 

11:45-12:45 pm  Lunch

12:45-1:15 pm Advances in Management of MDS: Rami Komrokji, MD

1:20-1:50 pm Advances in AML Management: Curtis Lachowiez, MD

1:55-2:05 pm Q & A

2:05-2:25 pm  Break

2:25-2:55 pm CLL in 2024: Evolution of the Role of  Novel Targeted Therapies: Catherine Coombs, MD

3:00-3:30 pm Updates in the Treatment of Indolent Lymphomas: Farrukh Awan, MD

3:35-3:45 pm  Q&A

3:50-4:10 pm  Break

4:10-4:40 pm Advances in Cellular Therapeutics: Joseph Maakaron, MD 

                                 The Herzig Memorial Lecture

4:45-5:00 pm Closing Remarks
            

Nursing Symposium Agenda                                                                                                                                                                                                           

7:30 am Registration

8:50 am Welcome Remarks: Hannah Butler, APRN

9:00 am-09:30 am Optimization of Bone Marrow Transplant and Cellular Therapy Inpatient Care: Corinne Shamehdi, MPAS, PA-C

9:35 am-10:05 am Outpatient Care for Cellular Therapeutic Patient: Joseph Maakaron, MD

10:10 am-10:40 am Multiple Myeloma: Basics and Current Standards: Saad Usmani, MD

10:45 am-11:15 am AML:  Understanding the Disease and Its Current Standards: Curtis Lachowiez, MD

*Space permitting, nursing registrants may have the option of attending afternoon sessions of the main event listed above. 

Course Director

Mohamed Hegazi, MD
Assistant Professor of Medicine
Section Chief, Blood Cancers, Cellular Therapeutics and Transplantation
Associate Director, Hematology/Oncology Fellowship Program
UofL Health - Brown Cancer Center
Louisville, KY

Course Faculty

Farrukh T. Awan, MD, MS, MBA
Professor of Internal Medicine
Division of Hematology and Oncology
University of Texas Southwestern Medical Center

Catherine C. Coombs, MD
Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
UCI Health

Rami Komrokji, MD
Senior Member & Professor of Oncology Services
Vice Chair, Malignant Hematology Department
 Moffitt Cancer Center

Curtis Lachowiez, MD
Assistant Professor of Medicine
Division of Hematology/Medical Oncology
OHSU Knight Cancer Institute Center for Hematologic Malignancies

John P. Leonard, MD
Senior Associate Dean for Innovation and Initiatives
Chair (Interim), Weill Department of Medicine
Richart T. Silver Distinguished Professor of Hematology and Medical Oncology
Weill Cornell Medicine/New York Presbyterian

John Maakaron, MD
Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota

Krina Patel, MD, MSc
Associate Professor
Department of Lymphoma-Myeloma, Division of Cancer Medicine
Co-Director, Lymphoma Myeloma Cellular Therapy Program
Associate Program Director, MDACC Hematology Oncology Fellowship Program

Corinne Shamehdi, MPAS, PA-C, PA-C
Inpatient Lead APP, Hematology, BMT/Cellular Therapy
Tampa General Hospital Cancer Institute

Nicholas Short, MD
Associate Professor, Department of Leukemia
The University of Texas MD Anderson Cancer Center

Saad Usmani, MD, MBA, FACP
Myeloma Specialist & Cellular Therapist
Memorial Sloan Kettering Cancer Center   

Continuing Education Credit
Physician Credit - The University of Louisville Continuing Medical Education office designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation
The University of Louisville School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Nurses - This program has been approved by the Kentucky Board of Nursing for 5.4 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-24-1391. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content. Completion criteria to obtain CE's: Attend entire session and complete the evaluation,

Special Services
To request disability arrangements, please contact  Rebecca Thurman at (502) 718-6511 at least 14 days prior to the date of this program. Continuing Medical Education and Professional Development fully complies with the legal requirements of the ADA and the rules and regulations thereof.

Brochure
CLICK HERE for a copy of the course brochure (Available Soon)

Registration
Registration for this event is free but you must register in advance to allow for program planning. 

CLICK HERE to Register for the Full Day Main Symposium

CLICK HERE to Register for the Half Day Nursing Symposium

Acknowledgments
We thank our participating companies for their support of the Louisville Hematology Highlights 2024 conference,  a final listing of supporters and exhibitors will be available at the meeting.

Accreditation Disclosure
As a provider accredited by the ACCME, the Office of CME&PD, School of Medicine, University of Louisville, must ensure balance, independence, objectivity, and scientific rigor in all its accredited educational activities. All Planners, faculty, reviewers, and other persons that affected the content of this CME activity were required to submit a financial disclosure form from which relevant conflicts of interest were determined. If any relevant financial relationship(s) with ineligible companies were disclosed, the materials each of them prepared for this program (or influenced) were peer-reviewed and determined to be without ineligible company bias, were considered fair and balanced in terms of therapeutic options, and presented evidence-based content. All relevant financial relationships with ineligible organizations have been mitigated prior to this activity.

Learner Consent Statement
Names or contact information of learners will not be shared with any ineligible company or its agents without the explicit consent of the individual learner.